
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Click on a blogger below to view the latest posts
Distinguished Guest Blogger - Nada Logan Stotland, MD, MPH
H. Steven Moffic, MD
Michael Blumenfield, MD
James L. Knoll, IV, MD
Daniel Carlat, MD
Ronald Pies, MD
All Blog Posts




